Sign in

CIK 0001677077 · <br>Emerging growth company

Alzamend Neuro, Inc.

Sign in to watch
Ticker
ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Apr 30
Incorporated
DE
Entity type
operating
EIN
811822909
Phone
844-722-6333
Business address
480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4/A Open-market buy 10% owner bought 14,500 shares at an average $6.15 ($89,136)
  6. 4 Open-market buy 10% owner bought 14,000 shares at an average $6.37 ($89,136)
  7. S-8 Other Securities Offered to Employees in Benefit Plans
  8. 4 Open-market buy 10% owner bought 14,000 shares at an average $6.65 ($93,109)
  9. 4 Open-market buy 10% owner bought 26,000 shares at an average $7.53 ($195,661)
  10. 4 Open-market buy 10% owner bought 24,300 shares at an average $9.15 ($222,339)
  11. 4 Open-market buy 10% owner bought 12,000 shares at an average $8.39 ($100,680)
  12. SC 13D Stake Beneficial Ownership Report
  13. 4 Open-market buy 10% owner bought 74,000 shares at an average $9.29 ($687,117)
  14. 8-K Event Executive or director change
  15. 3 Insider Initial Statement of Ownership
  16. 4 Open-market buy 10% owner bought 2,000,000 shares at $5.00 ($10,000,000)
  17. CORRESP Other Correspondence Between Filers and SEC Staff
  18. 424B4 Offering Prospectus
  19. EFFECT Other Notice of Effectiveness
  20. 3 Insider Initial Statement of Ownership

Page 16 of 20 · 398 filings